Takeda Collaborates with Skyhawk Therapeutics to Develop RNA Splicing Modifiers for Neurodegenerative Diseases

 Takeda Collaborates with Skyhawk Therapeutics to Develop RNA Splicing Modifiers for Neurodegenerative Diseases

Takeda Collaborates with Skyhawk Therapeutics to Develop RNA Splicing Modifiers for Neurodegenerative Diseases

Shots:

  • Skyhawk to receive upfront, milestones & royalties on sales and will discover & preclinically develop targeted therapies utilizing its SkySTAR technology. Takeda to get an exclusive WW license to develop & commercialize targeted therapies for multiple neurodegenerative diseases
  • The focus of the agreement is to develop therapies directing central nervous system for improvement of targeted neurological disorders
  • Skyhawk’s SkySTAR technology involves RNA splicing, correcting the RNA expression in small molecule for neurological diseases

Click here to read full press release/ article | Ref: PRNewswire | Image: Biopharma-Reporter

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post